Trials / Unknown
UnknownNCT04255836
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
A Pilot Study of Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligo-metastatic non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months |
| DRUG | the first line chemotherapy for metastatic NSCLC | paclitaxel+carboplatin or pemetrexed+cisplatin |
| RADIATION | stereotactic body radiotherapy (SBRT) | SBRT total doses of 50-60Gy/≤10F |
Timeline
- Start date
- 2020-09-30
- Primary completion
- 2022-09-30
- Completion
- 2023-07-30
- First posted
- 2020-02-05
- Last updated
- 2020-02-05
Source: ClinicalTrials.gov record NCT04255836. Inclusion in this directory is not an endorsement.